Aclaris Therapeutics (NASDAQ:ACRS) said on Tuesday that the U.S. FDA has cleared its investigational new drug application to ...

Another reason for choosing a particular modality is that it is a team’s specialty. Strategic choices can be less about determining which modality best fits a potential target than about choosing a ...

In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living ...

“The transaction also facilitates the combination of different isotype functions into a single antibody molecule,” Wilson ...

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the ...

He also said that the merger opens up the prospect of combining different isotype functions into a single antibody molecule. These hybrid antibodies have the potential to activate multiple ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

“The transaction also facilitates the combination of different isotype functions into a single antibody molecule.” The deal expands Epsilogen’s pipeline with TigaTx’s TIGA-001—to be ...

The company is dropping its former lead molecule in favor of another antibody, RLYB116, which is being developed for a ...

Expanded collaboration leverages complementary expertise to unlock next-generation oncology therapeutics Focus on breakthrough ADC payloads and ...